NYSE - Nasdaq Real Time Price USD
Teva Pharmaceutical Industries Limited (TEVA)
34.42 +1.21 (+3.63%)
As of 12:55:32 PM EDT. Market Open.
Trade TEVA on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for TEVA
- Previous Close
33.21 - Open
33.32 - Bid 34.46 x 30000
- Ask 34.52 x 30000
- Day's Range
33.16 - 34.58 - 52 Week Range
14.99 - 37.35 - Volume
3,259,564 - Avg. Volume
6,235,067 - Market Cap (intraday)
40.074B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
25.68 - EPS (TTM)
1.34 - Earnings Date Jul 29, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 27, 2017
- 1y Target Est
40.90
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .
YTD Return
TEVA
10.27%
TA-125 (^TA125.TA)
11.47%
1-Year Return
TEVA
101.38%
TA-125 (^TA125.TA)
39.53%
3-Year Return
TEVA
351.64%
TA-125 (^TA125.TA)
0.00%
5-Year Return
TEVA
230.28%
TA-125 (^TA125.TA)
130.70%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
38.54B
Enterprise Value
51.71B
Trailing P/E
24.78
Forward P/E
16.00
PEG Ratio (5yr expected)
0.95
Price/Sales (ttm)
2.24
Price/Book (mrq)
4.70
Enterprise Value/Revenue
2.98
Enterprise Value/EBITDA
15.82
Financial Highlights
Profitability and Income Statement
Profit Margin
9.02%
Return on Assets (ttm)
6.38%
Return on Equity (ttm)
21.60%
Revenue (ttm)
17.35B
Net Income Avi to Common (ttm)
1.56B
Diluted EPS (ttm)
1.34
Balance Sheet and Cash Flow
Total Cash (mrq)
3.74B
Total Debt/Equity (mrq)
205.60%
Levered Free Cash Flow (ttm)
2.61B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
34.42
+3.63%
Mkt Cap 40.074B
Industry Drug Manufacturers—Specialty & Generic
5.12
+1.79%
Mkt Cap 642.305M
Industry Drug Manufacturers—Specialty & Generic
9.54
-13.94%
Mkt Cap 4.715B
Industry Drug Manufacturers—Specialty & Generic
33.02
+0.18%
Mkt Cap 7.643B
Industry Drug Manufacturers—Specialty & Generic
4.6050
-0.11%
Mkt Cap 556.369M
Industry Drug Manufacturers—Specialty & Generic
15.80
-0.28%
Mkt Cap 49.908B
Industry Drug Manufacturers—Specialty & Generic
5.04
+5.00%
Mkt Cap 1.882B
Industry Drug Manufacturers—Specialty & Generic
0.9305
-1.66%
Mkt Cap 417.251M
Industry Drug Manufacturers—Specialty & Generic
2.5400
+2.42%
Mkt Cap 11.324M
Industry Drug Manufacturers—Specialty & Generic
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreRaising target price to $38
Teva Pharmaceutical Industries Ltd. is the world's largest generic pharmaceutical manufacturer, with roughly 76 billion tablets and capsules produced annually. The company has roughly 37,000 employees and over 53 manufacturing facilities across more than 33 countries. One of every 12 prescriptions in the U.S. is filled with Teva products.
RatingPrice TargetThe major indices are mixed at midday on Tuesday as stocks take a breather
The major indices are mixed at midday on Tuesday as stocks take a breather following recent gains. The Fed rate meeting has started and new Chairman Kevin Warsh will have his debut press conference tomorrow. Crude oil is down another 3% at $77 per barrel. The yield on the 10-year note is at 4.45%. The VIX volatility index is at 16.
Teva: Upgrading Moat and Raising Valuation on Portfolio Improvements and Deep Pipeline
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
RatingPrice TargetTeva Earnings: Brushes Off Generics Competition With Strong Momentum in Branded Assets; FVE Raised
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
RatingPrice Target